{
    "2021-10-22": [
        [
            {
                "time": "",
                "orginal_text": "泛生子宣布与复星医药签订Seq-MRD?独家商业化合作协议",
                "features": {
                    "keywords": [
                        "泛生子",
                        "复星医药",
                        "Seq-MRD",
                        "独家合作",
                        "商业化协议"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "复星医药与泛生子达成独家合作 推动血液肿瘤监测服务国内落地",
                "features": {
                    "keywords": [
                        "复星医药",
                        "泛生子",
                        "独家合作",
                        "血液肿瘤",
                        "监测服务",
                        "国内落地"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "泛生子(GTH.US)与复星医药(02196.HK)达成独家合作，携手推动血液肿瘤监测服务在华落地",
                "features": {
                    "keywords": [
                        "泛生子",
                        "GTH.US",
                        "复星医药",
                        "02196.HK",
                        "独家合作",
                        "血液肿瘤",
                        "监测服务",
                        "在华落地"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "orginal_text": "舍得酒业：辟谣老酒利空后发布三季报，多空厮杀谁能笑到最后？",
                "features": {
                    "keywords": [
                        "舍得酒业",
                        "辟谣",
                        "老酒利空",
                        "三季报",
                        "多空厮杀"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "白酒",
                        "消费品"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "orginal_text": "国泰君安：新冠疫苗进入业绩兑现期，港股部分标的将受益",
                "features": {
                    "keywords": [
                        "国泰君安",
                        "新冠疫苗",
                        "业绩兑现期",
                        "港股",
                        "标的受益"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技",
                        "港股"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "每日理财观察：证监会正评估完善试点注册制各项安排",
                "features": {
                    "keywords": [
                        "证监会",
                        "试点注册制",
                        "评估完善",
                        "各项安排"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "政策",
                        "资本市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}